How did MDT's Cardiac and Vascular Group perform in Q3 2025?

Medtronic's Cardiac and Vascular Group showed positive performance in Q3 2025, despite some challenges:

1. **Revenue Growth**: The Cardiovascular segment reported a revenue rise of 3.7%, driven significantly by the adoption of pulsed field ablation systems. This indicates a strong market demand and successful product uptake.
2. **Organic Revenue Growth**: The group achieved an organic revenue growth of 5%, reflecting a solid performance and the ability to generate income from its core operations.
3. **Earnings Per Share (EPS)**: The group’s GAAP diluted EPS increased by 2% to $1.01, while the non-GAAP diluted EPS saw a more substantial increase of 7% to $1.39. This suggests that the group is not only growing its top line but also improving its profitability.
4. **Market Position**: The success of products like pulsed field ablation, Micra transcatheter pacing systems, PulseSelect systems, and Affera Sphere-9 systems highlights Medtronic's strong market position and ability to innovate. These products are likely contributing to the revenue growth and improved profitability.

Overall, Medtronic's Cardiac and Vascular Group had a robust performance in Q3 2025, marked by revenue growth, organic expansion, and increased profitability. The group's focus on innovation and market-leading products is key to its continued success.